^
Association details:
| Biomarker: | SAA1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | PD1 inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Evaluation of blood-based proteomic biomarkers associated with response to anti-PD-1 treatment in NSCLC.
Published date:
05/13/2020
Excerpt:
Group A is characterized by high expression of acute phase proteins (e.g. SAA1/2, CRP)...and Group C has high expression glycolysis related enzymes (ALDOA, GAPDH) and focal adhesion proteins (VCL)...Group A, with high levels of acute phase proteins, had poor overall survival relative to the other two families (HR = 2.2 [1.2-4.2], p = 0.003). Notably, Group C is comprised largely of Non-Responders (8/12) yet had improved overall survival relative to Group A (HR = 2.5 [1.2-5.0], p = 0.004).
DOI:
10.1200/JCO.2020.38.15_suppl.e21531
